The Employer’s COVID-19 Return to the Workplace Playbook

I saw this document and thought you might find it useful as we proceed through the coming months. There are some great checklists to help you remember things to consider, links to resources and more.

As the provincial governments in Canada proceed with cautiously reopening the doors to the economy, many employers are in the process of making plans for reopening their own doors and considering how to do so safely. Irrespective of government announcements, employers will need to make their own determinations as to whether, when and how they will reopen their physical workplaces, keeping in mind their duties to their employees and stakeholders. Having a rational and documented plan in place for reopening will be necessary to ensure a smooth transition back to work.

This guide outlines the key considerations for employers in putting together such plans. A comprehensive chart of return to work resources for employers from the World Health Organization, Center for Disease Control, the Canadian Federal Government and each Provincial Government and Provincial health authorities can be accessed via the link set out below.


TELUS 2020 Drug Data Trends & National Benchmark Report

Each year at our renewal meeting we discuss your employees claims as well as industry trends that drive costs. If you’re interested in learning more about these, the Telus report shares data from across the majority of the private payer industry.

A few highlights

  • The eligible monthly cost per insured increased 7.6% in 2019, compared to a decline of 2.4% in 2018.
  • Ontario’s OHIP+ program, which removed insureds under the age of 25 in that province from the book of business for all of 2018 and the first three months of 2019, certainly had an impact.
  • Eligible costs jumped by 10.2% in Ontario in 2019; when insureds under the age of 25 are removed, this drops to 5.4%.
  • The average annual eligible cost per claimant was $769.13, compared to $675.95 in 2015.
  • Generic drugs accounted for 63% of prescriptions filled by private drug plans in 2019, up from 58% five years ago.
  • Specialty drugs’ share of eligible costs has more than doubled in the past 10 years, from 14% in 2010 to 30% in 2019.

More information and the full report are here.